Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22

Gene Therapy

Volumn 6, Issue 1, 1999, Pages 12-21

  Dilber, M S ^a,b   Phelan, A ^c   Aints, A ^a,b   Mohamed, A J ^a,b,d   Elliott, G ^c   Edvard Smith, C I ^a,b   O'Hare, P ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MARIE CURIE RESEARCH INSTITUTE   (United Kingdom)

^d SÖDERTÖRN UNIVERSITY   (Sweden)

Author keywords

GCV; HSV 1; Protein delivery; tk; VP22

Indexed keywords

CARRIER PROTEIN; GANCICLOVIR; PRODRUG; THYMIDINE KINASE; VIRUS FUSION PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL STRAIN COS1; CHIMERA; CONTROLLED STUDY; ENZYME ACTIVATION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; ANTIMETABOLITES; COS CELLS; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; NEOPLASMS; PRODRUGS; RECOMBINANT FUSION PROTEINS; THYMIDINE KINASE; VIRAL STRUCTURAL PROTEINS;

ANIMALIA; DNA VIRUSES; HERPES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0032896455     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300838     Document Type: Article

References (26)

1. Marcel T, Grausz JD. The TMC Worldwide Gene Therapy Enrollment Report, end 1996. Hum Gene Ther 1997; 8: 775-800.
2. Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 1997; 3: 1354-1361.
3. Verma I, Somia N. Gene therapy problems, promises and prospects. Nature 1997; 389: 239-242.
4. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
5. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
6. Dilber MS et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997; 57: 1523-1528.
7. Ishii-Morita H et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Therapy 1997; 4: 244-251.
8. Ruch RJ. The role of gap junctional intercellular communication in neoplasia. Ann Clin Lab Sci 1994; 24: 216-231.
9. Shinoura N et al. Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy. J Neurosurg 1996; 84: 839-845.
10. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-233.
11. Vrionis FD et al. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk:) gene is dependent on connexin expression and cell communication via gap junctions. Gene Therapy 1997; 4: 577-585.
12. Kuriyama S et al. Tissue-specific expression of HSVtk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma. Int J Cancer 1997; 71: 470-475.
13. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-3864.
14. Rosolen A et al. In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma. Gene Therapy 1998; 5: 113-120.
15. Lechanteur C et al. HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis. Gene Therapy 1997; 4: 1189-1194.
16. Melcher A et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nature Med 1998; 4: 581-587.
17. Wallace H et al. Ganciclovir-induced ablation non-proliferating thyrocytes expressing herpes virus thymidine kinase occurs by p53-independent apoptosis. Oncogens 1996; 13: 55-61.
18. Hamel W, Magnelli L, Chiarugi VP, Isreal MA. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 1996; 56: 2697-2702.
19. Vile RG et al. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
20. Klatzmann D. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum Gene Ther 1996; 7: 255-267.
21. Ramesh R et al. In vivo analysis of the 'bystander effect': a cytokine cascade. Exp Hematol 1996; 24: 829-838.
22. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpes virus protein VP22. Nat Biotechnol 1998; 16: 440-443.
23. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980-990.
24. Pear WS, Nolan GP, Scott ML, Baltimore MA. Production of high-liter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-6.
25. Boussif O et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in invo: polyethylenimine. Proc Natl Acnd Sci USA 1995; 92: 7297-7301.
26. Honess RW, O'Hare P, Young D. Comparison of thymidine kinase activities induced in cells productively infected with herpes virus saimiri and herpes simplex virus. J Gen Virol 1982; 58: 237-249.